Valeant Pharma (VRX) CEO Pearson Says Company 'is Going to Survive'
Tweet
Share
E-mail
Get Alerts VRX Hot Sheet
Price: $23.40 --0%
Financial Fact:
Income from operations: 72.17M
Today's EPS Names:
SUNB, CULP, KFY, More
Financial Fact:
Income from operations: 72.17M
Today's EPS Names:
SUNB, CULP, KFY, More
Join SI Premium – FREE
With its conference call today, Valeant Pharma (NYSE: VRX) said it doesn't have contingency plans if the stock keeps falling and it will sustain a short-term hit in its dermatology business.
CEO Michael Pearson also the company "is going to survive" and this is a "difficult" period for shareholders and the company.
Shares of Valeant are modestly lower in early trading. For more commentary from today's call, click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple announces A20 Pro chip based on 2nm technology
- Core & Main, Inc (CNM) Tops Q3 EPS by 2c ; Offers Guidance
- ServiceTitan, Inc. (TTAN) Misses Q2 EPS by 1c, Offers Guidance
Create E-mail Alert Related Categories
Guidance, Management Comments, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
